certolizumab pegol   

GtoPdb Ligand ID: 6774

Synonyms: CDP870 | Cimzia® | PHA 738144
certolizumab pegol is an approved drug (FDA (2008), EMA (2009))
Compound class: Antibody
Comment: This therapeutic is a TNFα neutralising agent. Structurally it is a Fab' fragment of a TNFα-binding monoclonal antibody, which has polyethylene glycol (PEG) conjugated to a free cysteine residue in its hinge region (Cys227 of the heavy chain). Removing the Fc portion minimizes complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), two reactions known to cause unwanted side-effects in mAb therapies. PEGylation is used to increase the drug's half life, as Fab' fragments are normally rapidly degraded in vivo.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol

Compound class Antibody
Approved drug? Yes (FDA (2008), EMA (2009))
International Nonproprietary Names
INN number INN
8448 certolizumab pegol
CDP870 | Cimzia® | PHA 738144
Database Links
Specialist databases
IMGT/mAb-DB 242
Other databases
GtoPdb PubChem SID 178103380
PubChem SID 178103380
Search PubMed clinical trials certolizumab pegol
Search PubMed titles certolizumab pegol
Search PubMed titles/abstracts certolizumab pegol
Wikipedia Certolizumab_pegol